AxoGen Inc. (NASDAQ:AXGN) – Equities research analysts at Lake Street Capital issued their FY2018 earnings per share estimates for shares of AxoGen in a research note issued to investors on Wednesday. Lake Street Capital analyst B. Jackson expects that the brokerage will post earnings per share of $0.10 for the year. Lake Street Capital has a “Buy” rating and a $11.00 price objective on the stock.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.08). AxoGen had a negative net margin of 33.02% and a negative return on equity of 292.94%.

TRADEMARK VIOLATION NOTICE: This article was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark laws. The correct version of this article can be read at https://www.thecerbatgem.com/2016/11/29/lake-street-capital-comments-on-axogen-inc-s-fy2018-earnings-axgn.html.

Earnings History and Estimates for AxoGen (NASDAQ:AXGN)

A number of other equities research analysts also recently issued reports on the stock. Wedbush reaffirmed an “outperform” rating and set a $12.00 price target on shares of AxoGen in a research note on Friday. JMP Securities reissued a “buy” rating on shares of AxoGen in a research note on Tuesday, November 22nd.

Shares of AxoGen (NASDAQ:AXGN) remained flat at $8.45 on Monday. 158,291 shares of the stock were exchanged. The stock’s 50 day moving average price is $8.66 and its 200-day moving average price is $7.71. The firm’s market cap is $277.99 million. AxoGen has a one year low of $4.52 and a one year high of $9.88.

Hedge funds and other institutional investors have recently bought and sold shares of the company. UBS Group AG boosted its position in AxoGen by 991.7% in the first quarter. UBS Group AG now owns 97,946 shares of the company’s stock worth $525,000 after buying an additional 88,974 shares during the last quarter. Bank of New York Mellon Corp boosted its position in AxoGen by 196.8% in the second quarter. Bank of New York Mellon Corp now owns 80,580 shares of the company’s stock worth $555,000 after buying an additional 53,427 shares during the last quarter. California State Teachers Retirement System bought a new position in AxoGen during the second quarter worth approximately $348,000. Nationwide Fund Advisors bought a new position in AxoGen during the second quarter worth approximately $105,000. Finally, Vanguard Group Inc. boosted its position in AxoGen by 61.5% in the second quarter. Vanguard Group Inc. now owns 775,448 shares of the company’s stock worth $5,335,000 after buying an additional 295,294 shares during the last quarter. Hedge funds and other institutional investors own 52.42% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark laws. The correct version of this article can be read at https://www.thecerbatgem.com/2016/11/29/lake-street-capital-comments-on-axogen-inc-s-fy2018-earnings-axgn.html.

In related news, VP John P. Engels purchased 4,000 shares of the business’s stock in a transaction dated Friday, October 7th. The shares were purchased at an average cost of $7.50 per share, for a total transaction of $30,000.00. Following the completion of the acquisition, the vice president now owns 98,425 shares in the company, valued at approximately $738,187.50. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Karen L. Zaderej purchased 10,000 shares of the business’s stock in a transaction dated Friday, October 7th. The stock was bought at an average price of $7.50 per share, for a total transaction of $75,000.00. Following the completion of the acquisition, the chief executive officer now owns 242,147 shares of the company’s stock, valued at approximately $1,816,102.50. The disclosure for this purchase can be found here. 9.33% of the stock is currently owned by insiders.

5 Day Chart for NASDAQ:AXGN

Receive News & Stock Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related stocks with our FREE daily email newsletter.